skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8830

A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications

(4265) Views  (739) Full article downloads

Authors: Behzad Molavi, Negah Rassouli, Suveer Bagwe, Neda Rasouli

Published Date January 2007 Volume 2007:3(6) Pages 967 - 973
DOI: http://dx.doi.org/10.2147/VHRM.S

Behzad Molavi1, Negah Rassouli2, Suveer Bagwe1, Neda Rasouli2

Central Arkansas Veterans Healthcare System and University of Arkansas for Medical sciences, 1Division of cardiology and 2Division of Endocrinology, College of Medicine, Little Rock, Arkansas, USA

Abstract: The rising incidence of obesity and insulin resistance to epidemic proportions has closely paralleled the surge in the prevalence of diabetes and outpaced therapeutic advances in diabetes prevention and treatment. Current evidence points to obesity induced oxidative stress and chronic inflammation as the common denominators in the evolution of insulin resistance and diabetes. Of all the hypoglycemic agents in the pharmacological arsenal against diabetes, thiazolidinediones, in particular pioglitazone, as well as metformin appear to have additional effects in ameliorating oxidative stress and inflammation; rendering them attractive tools for prevention of insulin resistance and diabetes. In addition to their hypoglycemic and lipid modifying properties, pioglitazone and metformin have been shown to exert anti-oxidative and anti-inflammatory effects in vascular beds, potentially slowing the accelerated atherosclerosis in diabetes, which is the major cause of morbidity and mortality in the affected population. The combination of pioglitazone and metformin would thus appear to be an effective pharmacological intervention in prevention and treatment of diabetes. Finally, this review will address the currently available evidence on diabetic cardiomyopathy and the potential role of combination therapy with pioglitazone and metformin.

Keywords: insulin resistance, oxidative stress, inflammation, pioglitazone, metformin, atherosclerosis, diabetic cardiomyopathy








Readers of this article also read:

Treatment update: thiazolidinediones in combination with metformin for the treatment of type 2 diabetes
A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes
Isolated periaortitis: Clinical and imaging characteristics
Adult nontwin sib concordance rates for type 2 diabetes, hypertension and metabolic syndrome among Asian Indians: The Indian Atherosclerosis Research Study
Rationale for multiple risk intervention: The need to move from theory to practice
Exacerbation rate, health status and mortality in COPD – a review of potential interventions
Information technology in pharmacovigilance: Benefits, challenges, and future directions from industry perspectives
ABO and rhesus blood group distribution in Kurds
Retinal nerve fiber layer evaluation in multiple sclerosis with spectral domain optical coherence tomography
A discrete choice experiment evaluation of patients' preferences for different risk, benefit, and delivery attributes of insulin therapy for diabetes management
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University